Complexation approach for fixed dose tablet formulation of lopinavir and ritonavir: An anomalous relationship between stability constant, dissolution rate and saturation solubility

Journal of Inclusion Phenomena and Macrocyclic Chemistry

Volumn 73, Issue 1-4, 2012, Pages 75-85

  Goyal, Gaurav ^a   Vavia, Pradeep R ^a  

^a INSTITUTE OF CHEMICAL TECHNOLOGY   (India)

Author keywords

Bioavailability; Cyclodextrin; Dissolution rate; Lopinavir; Protease inhibitors; Ritonavir

Indexed keywords

EID: 84862613096     PISSN: 09230750     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10847-011-0022-7     Document Type: Article

References (24)

1. NA Roberts JA Martin D Kinchington AV Broadhurst JC Craig IB Duncan SA Galpin BK Handa J Kay A Krohn RW Lambert JH Merrett JS Mills KEB Parkes S Redshaw AJ Ritchie DL Taylor GJ Thomas PJ Machin 1990 Rational design of peptide-based HIV proteinase inhibitors Science 248 358 361 10.1126/science. 2183354 1:CAS:528:DyaK3cXktFOnu7w%3D
2. DD Richman 2001 HIV chemotherapy Nature 410 995 1001 10.1038/35073673 1:CAS:528:DC%2BD3MXjt1Kqs7Y%3D
3. M Boffito L Dickinson A Hill D Back G Moyle M Nelson C Higgs C Fletcher S Mandalia B Gazzard A Pozniak 2004 Pharmacokinetics of once-daily saquinavir/ritonavir in HIV-infected subjects: comparison with the standard twice-daily regimen Antivir. Ther. 9 423 429 1:CAS:528:DC%2BD2cXntVansro%3D
4. E Ribera RM Lopez M Diaz L Pou L Ruiz V Falco M Crespo C Azuaje I Ruiz I Ocana B Clotet A Pahissa 2004 Steady-state pharmacokinetics of a double-boosting regimen of saquinavir soft gel plus lopinavir plus minidose ritonavir in human immunodeficiency virus-infected adults Antimicrob. Agents Chemother. 48 4256 4262 10.1128/AAC.48.11.4256-4262.2004 1:CAS:528:DC%2BD2cXpvVyksLk%3D
5. M Lang JL Roesel 1993 HIV-1 protease inhibitors: development, status, and potential role in the treatment of AIDS Arch. Pharm. 326 921 924 10.1002/ardp.19933261202 1:CAS:528:DyaK2cXpsVCrsw%3D%3D
6. T Robins J Plattner 1993 HIV protease inhibitors: their anti-HIV activity and potential role in treatment J. AIDS 6 162 170 1:CAS:528:DyaK3sXisVKks7w%3D
7. RK Zeldin RA Petruschke 2004 Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients J. Antimicrob. Chemother. 53 4 9 10.1093/jac/dkh029 1:CAS:528:DC%2BD3sXhtVShsbrM
8. Zhu, T., Chiu, Y., Doan, T., Klein, C., Chang, M., Brun, S., Hanna, G., Awni, W.: New tablet formulation of Lopinavir/Ritonavir is bioequivalent to the capsule at a dose of 800/200 mg. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy. Poster H-1894 (2005)
9. K Fukushima S Terasaka K Haraya S Kodera Y Seki A Wada Y Ito N Shibata N Sugioka K Takada 2007 Pharmaceutical approach to HIV protease inhibitor atazanavir for bioavailability enhancement based on solid dispersion system Biol. Pharm. Bull. 30 733 738 10.1248/bpb.30.733 1:CAS:528:DC%2BD2sXls1aktbo%3D
10. HH Kupferschmidt KE Fattinger HR Ha F Follath S Krahenbuhl 1998 Grapefruit juice enhances the bioavailability of the HIV protease inhibitor saquinavir in man Br. J. Clin. Pharmacol. 45 355 359 10.1046/j.1365-2125.1998. t01-1-00687.x 1:CAS:528:DyaK1cXisV2nsr0%3D
11. BT Griffin CM Driscoll 2006 A comparison of intestinal lymphatic transport and systemic bioavailability of saquinavir from three lipid-based formulations in the anaesthetized rat model J. Pharm. Pharmacol. 58 917 925 10.1211/jpp.58.7.0006 1:CAS:528:DC%2BD28Xps1Shu78%3D
12. GV Betageri DV Deshmukh RB Gupta 2001 Oral sustained-release bioadhesive tablet formulation of didanosine Drug Dev. Ind. Pharm. 27 129 136 10.1081/DDC-100000479 1:CAS:528:DC%2BD3MXitVKrtb4%3D
13. F De Jaeghere E Allemann F Kubel B Galli R Cozens E Doelker R Gurny 2000 Oral bioavailability of a poorly water soluble HIV-1 protease inhibitor incorporated into pH-sensitive particles: effect of the particle size and nutritional state J. Control. Release 68 291 298 10.1016/S0168-3659(00)00272-8
14. BV Eerdenbrugh L Froyen JA Martens N Blaton P Augustijns M Brewster GV Mooter 2007 Characterization of physico-chemical properties and pharmaceutical performance of sucrose co-freeze-dried solid nanoparticulate powders of the anti-HIV agent loviride prepared by media milling Int. J. Pharm. 338 198 206 10.1016/j.ijpharm.2007.02.005
15. JS Torne PR Vavia 2006 Inclusion complexation of anti-HIV drug with β-cyclodextrin J. Incl. Phenom. Macrocycl. Chem. 56 253 259 10.1007/s10847-006-9092-3 1:CAS:528:DC%2BD28XhtFSitrfL
16. T Loftsson P Jarho M Masson T Jarvinen 2005 Cyclodextrins in drug delivery Expert Opin. Drug Deliv. 2 335 351 10.1517/17425247.2.1.335 1:CAS:528:DC%2BD2MXjsFantrY%3D
17. T Higuchi KA Connors 1965 Phase-solubility techniques Adv. Anal. Chem. Instr. 4 117 212 1:CAS:528:DyaF2MXktlGitrg%3D
18. T Loftsson D Hreinsdottir M Masson 2005 Evaluation of cyclodextrin solubilization of drugs Int. J. Pharm. 302 18 28 10.1016/j.ijpharm.2005.05.042 1:CAS:528:DC%2BD2MXpvVWju7w%3D
19. J Guo Q Ping G Jiang J Dong S Qi L Feng Z Li C Li 2008 Transport of leuprolide across rat intestine, rabbit intestine and Caco-2 cell monolayer Int. J. Pharm. 278 415 422 10.1016/j.ijpharm.2004.03.031
20. Jadhav, G.S., Vavia, P.R., Nandedkar, T.D.: Danazol-β-cyclodextrin binary system: a potential application in emergency contraception by the oral route. AAPSPharmSciTech. 8, Article 35 (2007)
21. Bilensoy, E., Rouf, M.A., Vural, I., Şen, M., HIncal, A.A.: Mucoadhesive, thermosensitive, prolonged-release vaginal gel for clotrimazole: β-cyclodextrin complex. AAPS PharmSciTech. 7 (2006)
22. M Boffito L Else D Back J Taylor S Khoo M Sousa A Pozniak B Gazzard G Moyle 2008 Pharmacokinetics of atazanavir/ritonavir once daily and lopinavir/ritonavir twice and once daily over 72 h following drug cessation Antivir. Ther. 13 901 907 1:CAS:528:DC%2BD1cXhsFCiurjI
23. Y Bai GY Xu X Xin HY Sun HX Zhang AY Hao XD Yang L Yao 2008 Interaction between cetyltrimethylammonium bromide and β-cyclodextrin: surface tension and interfacial dilational viscoelasticity studies Colloid. Polym. Sci. 286 1475 1484 10.1007/s00396-008-1918-7 1:CAS:528:DC%2BD1cXht1Wrs73P
24. S Onclin A Mulder J Huskens BJ Ravoo DN Reinhoudt 2004 Molecular printboards: # monolayers of β-cyclodextrins on silicon oxide surfaces Langmuir 20 5460 5466 10.1021/la049561k 1:CAS:528:DC%2BD2cXktlWrtb0%3D